Gossamer Bio, Inc.
General ticker "GOSS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $356.2M (TTM average)
Gossamer Bio, Inc. follows the US Stock Market performance with the rate: 45.0%.
Estimated limits based on current volatility of 2.2%: low 0.45$, high 0.55$
Factors to consider:
- Earnings expected soon, date: 2026-03-12 bmo
- Total employees count: 145 (+7.4%) as of 2024
- Top business risk factors: Clinical trial delays, Regulatory and compliance, Dependency on third parties, Geopolitical risks, Market competition
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.56$, 1.74$]
- 2025-12-31 to 2026-12-31 estimated range: [0.51$, 1.59$]
Financial Metrics affecting the GOSS estimates:
- Positive: with PPE of -3.3 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -1.79 <= 0.01
- Positive: Investing cash flow per share per price, % of 15.00 > -0.63
- Positive: Inventory ratio change, % of -12.94 <= -0.75
Short-term GOSS quotes
Long-term GOSS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $114.70MM |
| Operating Expenses | $218.59MM | $183.76MM | $174.62MM |
| Operating Income | $-218.59MM | $-183.76MM | $-59.92MM |
| Non-Operating Income | $-10.79MM | $3.94MM | $4.28MM |
| Interest Expense | $13.88MM | $13.51MM | $11.52MM |
| R&D Expense | $170.98MM | $145.30MM | $138.49MM |
| Income(Loss) | $-229.38MM | $-179.82MM | $-55.63MM |
| Taxes | $0.00MM | $0.00MM | $0.89MM |
| Profit(Loss)* | $-229.38MM | $-179.82MM | $-56.53MM |
| Stockholders Equity | $12.08MM | $62.77MM | $29.49MM |
| Assets | $272.45MM | $311.92MM | $315.29MM |
| Operating Cash Flow | $-187.03MM | $-159.16MM | $-3.47MM |
| Capital expenditure | $0.47MM | $0.00MM | $0.00MM |
| Investing Cash Flow | $-1.03MM | $-110.97MM | $29.02MM |
| Financing Cash Flow | $117.09MM | $190.15MM | $-11.49MM |
| Earnings Per Share** | $-2.71 | $-0.80 | $-0.25 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.